• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

D5F3免疫组化检测非小细胞肺癌患者ALK基因重排的疗效：一项系统评价和荟萃分析。

Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis.

作者信息

Ma Hu, Yao Wen-Xiu, Huang Lang, Jin Su-Han, Liu Da-Hai, Liu Yuan, Tian Xu, Tian Jin-Hui, Zhou Jian-Guo

机构信息

Department of Oncology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China.

Department of Oncology, Affiliated Cancer Hospital of Medical School, University of Electronic Science and Technology of China, Sichuan Cancer Hospital and Institute & Cancer, The Second People's Hospital of Sichuan Province, Chengdu, 610000, China.

出版信息

Oncotarget. 2016 Oct 25;7(43):70128-70142. doi: 10.18632/oncotarget.11806.

DOI:10.18632/oncotarget.11806
PMID:27602773
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5342540/
Abstract

We conducted a pooled analysis comparing the efficacy of an immunohistochemistry (IHC) assay using the D5F3 antibody with that of fluorescence in situ hybridization (FISH) for detecting ALK gene rearrangement in NSCLC patients. A total of 32 studies involving 5805 samples were included in this review. Pooled sensitivity for D5F3 IHC was 0.97 (95%CI: 0.93-0.98), specificity was 0.99 (95%CI: 0.98-1.00), PLR was 119.20 (95%CI: 57.79-245.89), NLR was 0.03 (95%CI: 0.02-0.07), DOR was 3526.66 (95%CI: 1344.71-9249.03), and AUROC was 1.00 (95%CI: 0.99-1.00). Meta-regression revealed that specimen type was a source of heterogeneity for specificity, and specimen type and FISH signal distance were sources of heterogeneity in the joint model. Subgroup analysis revealed that sensitivity and specificity were higher when the FISH signal distance standard was ≥ 2 than when it was ≥ 1. Sensitivity was higher for tumor specimens than for cell specimens; specificity was higher for cell specimens than for tumor specimens. In conclusion, the D5F3 IHC assay was nearly as effective as FISH for detection of ALK gene rearrangement in NSCLC patients.

摘要

我们进行了一项汇总分析，比较使用D5F3抗体的免疫组织化学（IHC）检测法与荧光原位杂交（FISH）检测非小细胞肺癌（NSCLC）患者ALK基因重排的疗效。本综述共纳入32项研究，涉及5805个样本。D5F3 IHC的汇总敏感性为0.97（95%CI：0.93 - 0.98），特异性为0.99（95%CI：0.98 - 1.00），阳性似然比（PLR）为119.20（95%CI：57.79 - 245.89），阴性似然比（NLR）为0.03（95%CI：0.02 - 0.07），诊断比值比（DOR）为3526.66（95%CI：1344.71 - 9249.03），曲线下面积（AUROC）为1.00（95%CI：0.99 - 1.00）。Meta回归显示，标本类型是特异性异质性的来源，标本类型和FISH信号距离是联合模型中异质性的来源。亚组分析显示，当FISH信号距离标准≥2时，敏感性和特异性高于≥1时。肿瘤标本的敏感性高于细胞标本；细胞标本的特异性高于肿瘤标本。总之，在检测NSCLC患者的ALK基因重排方面，D5F3 IHC检测法与FISH几乎同样有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/784a4405ab0f/oncotarget-07-70128-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/a31b36bb90f9/oncotarget-07-70128-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/021985268802/oncotarget-07-70128-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/ed0e06b86ff1/oncotarget-07-70128-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/6d0f11675a00/oncotarget-07-70128-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/df115c444dfa/oncotarget-07-70128-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/350968a95836/oncotarget-07-70128-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/fe45f91d6e3f/oncotarget-07-70128-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/7dcc563aaf36/oncotarget-07-70128-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/48d8e528f6a2/oncotarget-07-70128-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/784a4405ab0f/oncotarget-07-70128-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/a31b36bb90f9/oncotarget-07-70128-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/021985268802/oncotarget-07-70128-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/ed0e06b86ff1/oncotarget-07-70128-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/6d0f11675a00/oncotarget-07-70128-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/df115c444dfa/oncotarget-07-70128-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/350968a95836/oncotarget-07-70128-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/fe45f91d6e3f/oncotarget-07-70128-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/7dcc563aaf36/oncotarget-07-70128-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/48d8e528f6a2/oncotarget-07-70128-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c584/5342540/784a4405ab0f/oncotarget-07-70128-g010.jpg

相似文献

1
Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis.D5F3免疫组化检测非小细胞肺癌患者ALK基因重排的疗效：一项系统评价和荟萃分析。
Oncotarget. 2016 Oct 25;7(43):70128-70142. doi: 10.18632/oncotarget.11806.
2
ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis.用于非小细胞肺癌中ALK基因重排筛查的ALK免疫组化：一项系统评价和荟萃分析。
Int J Biol Markers. 2016 Dec 23;31(4):e413-e421. doi: 10.5301/jbm.5000218.
3
Targeted therapy for advanced anaplastic lymphoma kinase (<I>ALK</I>)-rearranged non-small cell lung cancer.晚期间变性淋巴瘤激酶（<I>ALK</I>）重排非小细胞肺癌的靶向治疗。
Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD013453. doi: 10.1002/14651858.CD013453.pub2.
4
Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).比较四种不同的ALK抗体与手工免疫组织化学（IHC）用于筛查ALK重排的非小细胞肺癌（NSCLC）。
Lung Cancer. 2015 Dec;90(3):492-8. doi: 10.1016/j.lungcan.2015.10.002. Epub 2015 Oct 21.
5
High concordance between Immunohistochemistry and RT-PCR in diagnosing ALK rearrangement in lung adenocarcinoma cytologic samples.免疫组织化学与逆转录聚合酶链反应在诊断肺腺癌细胞学样本中ALK重排方面具有高度一致性。
Med J Malaysia. 2025 May;80(3):366-372.
6
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.晚期表皮生长因子受体（EGFR）突变阳性非鳞状非小细胞肺癌的一线治疗
Cochrane Database Syst Rev. 2016 May 25(5):CD010383. doi: 10.1002/14651858.CD010383.pub2.
7
Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.染色体臂 1p 和 19q 缺失的检测在胶质瘤患者中的诊断准确性和成本效益。
Cochrane Database Syst Rev. 2022 Mar 2;3(3):CD013387. doi: 10.1002/14651858.CD013387.pub2.
8
Effect of ALK-inhibitors in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.ALK 抑制剂治疗非小细胞肺癌的疗效：系统评价和荟萃分析。
Eur Rev Med Pharmacol Sci. 2017 Aug;21(15):3496-3503.
9
Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.免疫组织化学是一种可靠的筛选工具，可用于鉴定非小细胞肺癌中的 ALK 重排，并且依赖于抗体。
J Thorac Oncol. 2013 Jan;8(1):45-51. doi: 10.1097/JTO.0b013e318274a83e.
10
Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.免疫组织化学作为检测黑色素瘤中BRAF-V600E突变的可靠方法：对当前已发表文献的系统评价和荟萃分析
J Surg Res. 2016 Jun 15;203(2):407-15. doi: 10.1016/j.jss.2016.04.029. Epub 2016 Apr 23.

引用本文的文献

1
Genomic and Glycolytic Entropy Are Reliable Radiogenomic Heterogeneity Biomarkers for Non-Small Cell Lung Cancer.基因组和糖酵解熵是非小细胞肺癌可靠的放射基因组异质性生物标志物。
Int J Mol Sci. 2023 Feb 16;24(4):3988. doi: 10.3390/ijms24043988.
2
Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine.将系统医学转化为临床实践：来自肺病学的实例，涉及遗传性疾病、感染、炎症、癌症发生以及非小细胞肺癌分子改变的治疗意义与个性化医疗。
Front Med (Lausanne). 2019 Oct 29;6:233. doi: 10.3389/fmed.2019.00233. eCollection 2019.
3

本文引用的文献

1
The Adverse Events of Oxycodone in Cancer-Related Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.羟考酮用于癌症相关疼痛的不良事件：随机对照试验的系统评价和荟萃分析
Medicine (Baltimore). 2016 Apr;95(15):e3341. doi: 10.1097/MD.0000000000003341.
2
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.NCCN指南解读：非小细胞肺癌，2016年第4版
J Natl Compr Canc Netw. 2016 Mar;14(3):255-64. doi: 10.6004/jnccn.2016.0031.
3
Improving Selection Criteria for ALK Inhibitor Therapy in Non-Small Cell Lung Cancer: A Pooled-Data Analysis on Diagnostic Operating Characteristics of Immunohistochemistry.
Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.
非小细胞肺癌中 ALK 融合断点的基因组异质性。
Mod Pathol. 2018 May;31(5):791-808. doi: 10.1038/modpathol.2017.181. Epub 2018 Jan 12.
4
Systematic review and meta-analysis of the efficacy of serum neuron-specific enolase for early small cell lung cancer screening.血清神经元特异性烯醇化酶用于早期小细胞肺癌筛查疗效的系统评价与Meta分析
Oncotarget. 2017 May 11;8(38):64358-64372. doi: 10.18632/oncotarget.17825. eCollection 2017 Sep 8.
改善非小细胞肺癌中ALK抑制剂治疗的选择标准：免疫组织化学诊断操作特征的汇总数据分析
Am J Surg Pathol. 2016 May;40(5):697-703. doi: 10.1097/PAS.0000000000000604.
4
The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis.厄洛替尼与传统化疗治疗晚期非小细胞肺癌的疗效：一项符合PRISMA标准的系统评价及Meta回归与Meta分析
Medicine (Baltimore). 2016 Jan;95(2):e2495. doi: 10.1097/MD.0000000000002495.
5
Cancer statistics, 2016.癌症统计数据，2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
6
[Anaplastic lymphoma kinase-positive adenocarcinoma of lung: a cytopathologic analysis].[肺间变性淋巴瘤激酶阳性腺癌：细胞病理学分析]
Zhonghua Bing Li Xue Za Zhi. 2015 Sep;44(9):628-32.
7
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.克唑替尼治疗后进展的间变性淋巴瘤激酶阳性非小细胞肺癌患者中阿来替尼的疗效：一项全球 II 期研究。
J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/jco.2015.63.9443. Epub 2015 Nov 23.
8
Efficacy of bronchoscopic biopsy for the detection of epidermal growth factor receptor mutations and anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma.支气管镜活检检测肺腺癌中表皮生长因子受体突变和间变性淋巴瘤激酶基因重排的疗效。
Thorac Cancer. 2015 Nov;6(6):709-14. doi: 10.1111/1759-7714.12245. Epub 2015 Mar 6.
9
Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).比较四种不同的ALK抗体与手工免疫组织化学（IHC）用于筛查ALK重排的非小细胞肺癌（NSCLC）。
Lung Cancer. 2015 Dec;90(3):492-8. doi: 10.1016/j.lungcan.2015.10.002. Epub 2015 Oct 21.
10
Detection of EML4-ALK fusion gene in Chinese non-small cell lung cancer by using a sensitive quantitative real-time reverse transcriptase PCR technique.运用灵敏的定量实时逆转录聚合酶链反应技术检测中国非小细胞肺癌中的EML4-ALK融合基因。
Appl Immunohistochem Mol Morphol. 2015 Apr;23(4):245-54. doi: 10.1097/PDM.0000000000000038.